Literature DB >> 16646051

Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: A prospective cohort study.

Reiko Suzuki1, Tove Rylander-Rudqvist, Weimin Ye, Shigehira Saji, Alicja Wolk.   

Abstract

Although obesity is one of the established risk factors for postmenopausal breast cancer, it is not clear whether this positive association differs across estrogen receptor (ER) and progesterone receptor (PR) status of breast tumors. We evaluated the association between body weight and ER/PR defined breast cancer risk stratified by postmenopausal hormone (PMH) use and a family history of breast cancer in the population-based Swedish Mammography Screening Cohort comprising 51,823 postmenopausal women. Relative body weight was measured by body mass index (kg/m2) based on self-reported weight and height collected in 1987 and 1997. Relative risks (RRs) were estimated by hazard ratios derived from Cox proportional hazards regression models. During an average of 8.3-year follow-up, 1,188 invasive breast cancer cases with known ER and PR status were diagnosed. When comparing to normal weight group, we observed a positive association between obesity and risk for the development of ER+ PR+ tumors (RR = 1.67, 95% CI = 1.34-2.07) and an inverse association for the development of all PR- tumors (RR = 0.68, 95% CI = 0.47-0.98). Statistically significant heterogeneity was observed in the RRs between ER+ PR+ tumors and all PR- tumors (p(heterogeneity) < 0.0001). The positive association of obesity with the development of ER+ PR+ tumors was confined to never-users of PMHs (RR = 1.90 (CI 95%:1.38-2.61)) and to those without a family history of breast cancer (RR = 1.82 (CI 95%:1.45-2.29)). Our results support the hypothesis that excess endogenous estrogen due to obesity contributes to an increased risk of ER+ PR+ postmenopausal breast cancer. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16646051     DOI: 10.1002/ijc.22034

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  46 in total

1.  A case-control study of body mass index and breast cancer risk in white and African-American women.

Authors:  Paula Berstad; Ralph J Coates; Leslie Bernstein; Suzanne G Folger; Kathleen E Malone; Polly A Marchbanks; Linda K Weiss; Jonathan M Liff; Jill A McDonald; Brian L Strom; Michael S Simon; Dennis Deapen; Michael F Press; Ronald T Burkman; Robert Spirtas; Giske Ursin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

Review 2.  Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status.

Authors:  Mark F Munsell; Brian L Sprague; Donald A Berry; Gary Chisholm; Amy Trentham-Dietz
Journal:  Epidemiol Rev       Date:  2014       Impact factor: 6.222

3.  Impact of body mass index on prognostically relevant breast cancer tumor characteristics.

Authors:  Monika Eichholzer; Dorothy J Huang; Alexandra Modlasiak; Seraina M Schmid; Andreas Schötzau; Sabine Rohrmann; Uwe Güth
Journal:  Breast Care (Basel)       Date:  2013-06       Impact factor: 2.860

4.  Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study.

Authors:  Ping-Ping Bao; Xiao Ou Shu; Yu-Tang Gao; Ying Zheng; Hui Cai; Sandra L Deming; Zhi-Xian Ruan; Yinghao Su; Kai Gu; Wei Lu; Wei Zheng
Journal:  Am J Epidemiol       Date:  2011-07-18       Impact factor: 4.897

5.  The Relationship between Bone Mineral Density and Estrogen Receptor Positivity in Patients with Breast Cancer.

Authors:  Zeynep Erdoğan İyigün; Kezban Nur Pilancı; Fatmagül Kuşku Çabuk; Serkan İlgün; Çetin Ordu; Tomris Duymaz; Gül Alço; Filiz Çelebi; Dauren Sarsenov; Filiz İzci; Alper Öztürk; Filiz Ağaçayak; Ülkühan İner Köksal; Fatma Aktepe; Yeşim Eralp; Vahit Özmen
Journal:  J Breast Health       Date:  2016-07-01

6.  Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831.

Authors:  Jennifer A Crozier; Alvaro Moreno-Aspitia; Karla V Ballman; Amylou C Dueck; Barbara A Pockaj; Edith A Perez
Journal:  Cancer       Date:  2013-04-12       Impact factor: 6.860

7.  Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women.

Authors:  Amanda I Phipps; Kathleen E Malone; Peggy L Porter; Janet R Daling; Christopher I Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-07-29       Impact factor: 4.254

8.  Postmenopausal hormone replacement therapy and risk of acute pancreatitis: a prospective cohort study.

Authors:  Viktor Oskarsson; Nicola Orsini; Omid Sadr-Azodi; Alicja Wolk
Journal:  CMAJ       Date:  2014-01-27       Impact factor: 8.262

9.  Alcohol and folate intake and breast cancer risk in the WHI Observational Study.

Authors:  Christine M Duffy; Annlouise Assaf; Michele Cyr; Gary Burkholder; Elizabeth Coccio; Tom Rohan; Anne McTiernan; Electra Paskett; Dorothy Lane; V K Chetty
Journal:  Breast Cancer Res Treat       Date:  2008-09-11       Impact factor: 4.872

10.  Triple-negative breast cancers are increased in black women regardless of age or body mass index.

Authors:  Lesley A Stead; Timothy L Lash; Jerome E Sobieraj; Dorcas D Chi; Jennifer L Westrup; Marjory Charlot; Rita A Blanchard; John C Lee; Thomas C King; Carol L Rosenberg
Journal:  Breast Cancer Res       Date:  2009-03-25       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.